Skip to main content
Equibles
GUTS logo

GUTS · Fractyl Health, Inc.

Track GUTS — free

Use GUTS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about GUTS

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.68 +0.02 (+2.72%) At close · Aug 14
Going-concern doubt — flagged Aug 10, 2026

Substantial doubt about the company's ability to continue as a going concern.

“However, these existing cash resources are not expected to be sufficient to fund the Company's current operating plan for at least twelve months from the issuance date of this Quarterly Report on Form 10-Q. As a result, substantial doubt exists about the Company's ability to continue as a going concern for at least one year after the date that these financial statements are issued.”
View the 10-Q filed Aug 10, 2026
Market Cap
$108.24M
Shares
159.18M

Fractyl Health, Inc. Earnings Call Transcripts

Every quarterly earnings call for Fractyl Health, Inc. (GUTS) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲560% $33,000 −$3.32M '24 Q1 24-05-13 ▼40.3% $43,000 −$17.23M '24 Q2 24-08-14 ▼61.1% $14,000 −$23.17M '24 Q3 24-11-12 LATEST ▼57.1% $3,000 −$24.97M '24 Q4 25-03-03
Conference
Investor event
2026-08-12
Canaccord Genuity 46th Annual Growth Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-10
REMAIN-1 Midpoint One-Year Results Conference Call
Diluted EPS
$-0.16
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
Fractyl Health, Inc. Q1 FY2026 Earnings Call
Confident tone IP portfolio GLP-1 market dynamics and post-GLP-1 rebound Pivotal trial execution (Remain One)
Diluted EPS
$0.06
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-24
Fractyl Health, Inc. Q4 FY2025 Earnings Call
Confident tone Revita dose-response (ablation length) REMAIN-1 pivotal study design and readout timeline Regulatory pathway and FDA feedback
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q4
2026-01-29
REMAIN-1 Midpoint Cohort 6-month Randomized Results Conference Call
Confident tone Revita dose-response (ablation length) REMAIN-1 pivotal study design and readout timeline Regulatory pathway and FDA feedback
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-12
Fractyl Health, Inc. Q3 FY2025 Earnings Call
Confident tone Revita Clinical Data and Durability Remain 1 Pivotal Trial Progress Upcoming Clinical Catalysts and Regulatory Path
Diluted EPS
$-0.71
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Fractyl Health, Inc. Q2 FY2025 Earnings Call
Confident tone Revita / REMAIN-1 pivotal study and randomized readout Weight regain after GLP-1 discontinuation (unmet need) German real-world registry durability data
Diluted EPS
$-0.57
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Fractyl Health, Inc. Q1 FY2025 Earnings Call
Confident tone Remain-1 pivotal enrollment completion Rejuva / RJVA-001 gene therapy platform Regulatory progress and FDA interactions
Diluted EPS
$-0.49
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-03
Fractyl Health, Inc. Q4 FY2024 Earnings Call
Confident tone Revita / REMAIN-1 pivotal study in weight maintenance Rejuva gene therapy platform REVEAL-1 open-label early data
Revenue
$3,000*
▼ 57.1% YoY
Gross margin
100.0%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Fractyl Health, Inc. Q3 FY2024 Earnings Call
Confident tone GLP-1 limitations and durability concerns Rejuva gene therapy platform and preclinical data Revita REMAIN-1 pivotal study for weight maintenance
Revenue
$14,000
▼ 61.1% YoY
Diluted EPS
$-0.48
Gross margin
50.0%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Fractyl Health, Inc. Q2 FY2024 Earnings Call
Positive tone Revita Breakthrough Device Designation REMAIN-1 Weight Maintenance Study Rejuva Gene Therapy Platform
Revenue
$43,000
▼ 40.3% YoY
Diluted EPS
$-0.36
Gross margin
44.2%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Fractyl Health, Inc. Q1 FY2024 Earnings Call
Confident tone Revita Remain-1 Pivotal Study in Obesity Revitalize-1 Pivotal Trial in Type 2 Diabetes Rejuva Gene Therapy Platform / RJVA-001
Revenue
$33,000
▲ 560% YoY
Diluted EPS
$-0.17
Gross margin
42.4%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–12 of 12 earnings calls
Key facts CIK 1572616 CUSIP 35168W103 13F (30d) 73 filings 73 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)